Skip to content

Study · Observational study · n = 13 · 1997

3 results

Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulin-dependent diabetes mellitus.

Villas-Boas Weffort RF, Ramos-Dias JC, Chipoch C, Lengyel AM

Metabolism: clinical and experimental1 Jun 1997Cited by 5 (Europe PMC)

PMID9186309 (opens in a new tab)DOI10.1016/s0026-0495(97)90017-2 (opens in a new tab)PepBankPUB-09186309
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with insulin-dependent diabetes and controls, the peak GH after GHRP‑6 was similar.

    In plain wordsIn people with type 1 diabetes and in controls, GHRP‑6 raised growth hormone to a similar level.

    Peptide
    GHRP-6
    Outcome
    No significant changePeak GH after GHRP-6 in IDDM versus controls
    Study

    n = 13

    Comparator
    Control subjects
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    GH peak values (mean +/- SE in micrograms per liter) were similar in controls and diabetics after GHRH (22.5 +/- 7.8 v 24.0 +/- 9.7) and after GHRP-5 (20.5 +/- 5.3 v 24.4 +/- 6.3).
    2 context sentences
    Summary · context
    Six patients with IDDM and seven control subjects were studied.
    Summary · context
    Each subject received GHRP-6 (1 microgram/kg intravenously [IV]), GHRH (100 micrograms IV), and GHRP-6 + GHRH on 3 separate days.

Studies that did not test the peptide alone2

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 02HumanNot a test of GHRP-6 aloneObservational studyEfficacy outcome

    In patients with insulin-dependent diabetes and in controls, GHRP‑6 plus GHRH induced significantly higher GH release than either peptide alone.

    In plain wordsIn people with type 1 diabetes and in controls, GHRP‑6 with GHRH raised growth hormone more than either peptide alone.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH release after GHRP-6 plus GHRH versus each peptide alone
    Study

    n = 13

    Comparator
    GHRP-6 alone or GHRH alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The association of GHRP-6 and GHRH induced a significantly higher GH release than administration of the isolated peptides in both groups.
    2 context sentences
    Summary · context
    Six patients with IDDM and seven control subjects were studied.
    Summary · context
    Each subject received GHRP-6 (1 microgram/kg intravenously [IV]), GHRH (100 micrograms IV), and GHRP-6 + GHRH on 3 separate days.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 03HumanNot a test of GHRP-6 aloneObservational studyEfficacy outcome

    The synergistic GH response to GHRP‑6 plus GHRH was not different between patients with insulin-dependent diabetes and controls.

    In plain wordsGHRP‑6 with GHRH gave a similar boost in growth hormone in people with type 1 diabetes and in controls.

    Peptide
    GHRP-6
    Outcome
    No significant changeSynergistic GH response to GHRP-6 plus GHRH in IDDM versus controls
    Study

    n = 13

    Comparator
    Control subjects
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The synergistic GH response to combined administration of GHRP-6 and GHRH was not different in controls (70.5 +/- 20.0) and diabetics (119.0 +/- 22.2).
    2 context sentences
    Summary · context
    Six patients with IDDM and seven control subjects were studied.
    Summary · context
    Each subject received GHRP-6 (1 microgram/kg intravenously [IV]), GHRH (100 micrograms IV), and GHRP-6 + GHRH on 3 separate days.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.